https://doi.org/10.55788/00f9a295
Assessment of mean platelet volume, tryptase, and age may help to pick the right treatment for paediatric patients with chronic spontaneous urticaria (CSU). The authors of this single-centre retrospective study emphasised that this result should be confirmed in a larger trial. Despite this limitation, the study won the second poster prize at the AAD 2023 meeting.
Until present, there are very few studies on biomarkers for CSU in children. Therefore, Mr Alex Nguyen (McGill University, Canada) aimed to better understand the role of different biomarkers in treatment response and disease resolution in children with CSU.
Data was obtained from 109 children from the Montreal Children’s Hospital Allergy and Immunology Clinic who reported hives for at least 6 weeks from 2013 to 2022. The mean age of the children was 9 years and 55% of the study population were girls. The researchers obtained levels of thyroid stimulating hormone (TSH), anti-thyroxine peroxidase (anti-TPO), total immunoglobulin E (IgE), CD63, tryptase, eosinophils, mean platelet volume (MPV), and platelets. Diseases activity was recorded at study entry using the weekly urticaria activity score (UAS7).
Univariate and multivariate logistic regressions were compared to determine factors associated with different treatment levels, namely antihistamines at the standard dose, at 4 times the standard dose, omalizumab, and resolution of treatment.
According to the results of the univariate analysis, elevated levels of MPV were associated with use of 4 times the standard dose of antihistamines treatment level, whereas younger age was associated with disease resolution. In the multivariate logistic analysis adjusted for age, sex TSH, anti-TPO, total IgE, CD63, eosinophils, MPV, and platelets, elevated tryptase levels were associated with antihistamines use at the standard dose (OR 1.15; 95% CI 1.02–1.30) and lower tryptase levels with disease resolution (OR 0.86; 95% CI 0.78‒0.96).
Although these results should be confirmed in a larger study, the authors conclude that the underlying mechanisms of tryptase may help identify paediatric patients with CSU who will respond to different treatment options.
- Nguyen A, et al. Association of Biomarkers with Treatment and Disease Resolution of Chronic Spontaneous Urticaria in Children. P43608, AAD 2023 Annual Meeting, 17–21 March, New Orleans, USA.
Posted on
« Izokibep shows remarkably high grades of clinical response in HS Next Article
JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata »
Table of Contents: AAD 2023
Featured articles
New Developments in Dermatology
Delgocitinib shows promise as topical therapy for chronic hand eczema
Vitiligo patients maintain re-pigmentation after ruxolitinib cream withdrawal
Nemolizumab decreases lesions and itch in prurigo nodularis
Lichen planus: a future indication for baricitinib?
Atopic Dermatitis: State of the Art
As-needed ruxolitinib shows successful long-term symptom control in AD
Dupilumab: a viable option for atopic hand and foot eczema
Topical roflumilast beneficial in atopic dermatitis
IL-22 receptor blocker reduces itch and skin lesions in AD
Psoriasis: New Developments
Switching to risankizumab successful in IL-17 inhibitor non-responders
Novel, selective TYK2 inhibitor shows promise for psoriasis
Hidradenitis Suppurativa: What You Need to Know
Izokibep shows remarkably high grades of clinical response in HS
Bimekizumab could be the new up-and-comer for HS treatment
Pearls of the Posters
Biologics in psoriasis: can they prevent joint involvement?
JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
Biomarkers predicting response of different CSU treatments in children
Related Articles

AAD 2020 Highlights Podcast
Age at disease onset: a key factor in understanding psoriasis
© 2023 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy